Title: A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.
Journal: Nature chemical biology 20151201
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia.
Journal: Leukemia & lymphoma 20120801
Title: 3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Journal: Bioorganic & medicinal chemistry letters 20120715
Title: FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model.
Journal: Cancer chemotherapy and pharmacology 20120601
Title: An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.
Journal: Cancer chemotherapy and pharmacology 20120601
Title: A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model.
Journal: Cancer chemotherapy and pharmacology 20120401
Title: BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML.
Journal: British journal of cancer 20120131
Title: Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.
Journal: European journal of cancer (Oxford, England : 1990) 20111201
Title: A comparative study of dynamic contrast-enhanced MRI parameters as biomarkers for anti-angiogenic drug therapy.
Journal: NMR in biomedicine 20111101
Title: Comprehensive analysis of kinase inhibitor selectivity.
Journal: Nature biotechnology 20111030
Title: Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110801
Title: Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Journal: Bioorganic & medicinal chemistry 20110715
Title: ABT-869, a multitargeted receptor tyrosine kinase inhibitor, reduces tumor microvascularity and improves vascular wall integrity in preclinical tumor models.
Journal: The Journal of pharmacology and experimental therapeutics 20110701
Title: Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Journal: European journal of medicinal chemistry 20110601
Title: The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway.
Journal: Molecular cancer therapeutics 20110601
Title: Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
Journal: Chemistry & biology 20101124
Title: Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future.
Journal: Oncotarget 20101101
Title: Linifanib.
Journal: Drugs in R&D 20100701
Title: ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways.
Journal: Molecular cancer therapeutics 20100301
Title: Three dimensional pharmacophore modelling for c-Kit receptor tyrosine kinase inhibitors.
Journal: European journal of medicinal chemistry 20100101
Title: Pulse-modulated second harmonic imaging microscope quantitatively demonstrates marked increase of collagen in tumor after chemotherapy.
Journal: Journal of biomedical optics 20100101
Title: Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091001
Title: Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition.
Journal: The Journal of pharmacology and experimental therapeutics 20090601
Title: Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML.
Journal: Blood 20090423
Title: ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats.
Journal: Journal of cardiovascular pharmacology 20090201
Title: ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.
Journal: Journal of hematology & oncology 20090101
Title: Simultaneous determination of a hydrophobic drug candidate and its metabolite in human plasma with salting-out assisted liquid/liquid extraction using a mass spectrometry friendly salt.
Journal: Journal of pharmaceutical and biomedical analysis 20081201
Title: ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft.
Journal: Journal of hepatology 20081201
Title: 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
Journal: Journal of medicinal chemistry 20080710
Title: In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor.
Journal: Leukemia research 20080701
Title: 3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases.
Journal: Journal of medicinal chemistry 20080313
Title: Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway.
Journal: Leukemia 20080101
Title: Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20080101
Title: A quantitative analysis of kinase inhibitor selectivity.
Journal: Nature biotechnology 20080101
Title: ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.
Journal: Blood 20070415
Title: Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor.
Journal: Journal of medicinal chemistry 20070405
Title: Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20060801
Title: Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.
Journal: Molecular cancer therapeutics 20060401
Title: Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors.
Journal: Molecular cancer therapeutics 20060401
Title: A high-throughput, fully automated liquid/liquid extraction liquid chromatography/mass spectrometry method for the quantitation of a new investigational drug ABT-869 and its metabolite A-849529 in human plasma samples.
Journal: Rapid communications in mass spectrometry : RCM 20060101
Title: A high-throughput liquid chromatography/tandem mass spectrometry method for simultaneous quantification of a hydrophobic drug candidate and its hydrophilic metabolite in human urine with a fully automated liquid/liquid extraction.
Journal: Rapid communications in mass spectrometry : RCM 20060101
